NASDAQ:OVID - Ovid Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.28 -0.45 (-5.15 %)
(As of 05/22/2018 02:09 AM ET)
Previous Close$8.73
Today's Range$8.14 - $8.91
52-Week Range$5.28 - $15.05
Volume53,800 shs
Average Volume93,155 shs
Market Capitalization$214.96 million
P/E Ratio-2.47
Dividend YieldN/A
BetaN/A

About Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics logoOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661

Debt

Debt-to-Equity RatioN/A
Current Ratio11.52
Quick Ratio11.52

Price-To-Earnings

Trailing P/E Ratio-2.47
Forward P/E Ratio-3.42
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.39 per share
Price / Book2.44

Profitability

EPS (Most Recent Fiscal Year)($3.35)
Net Income$-64,800,000.00
Net MarginsN/A
Return on Equity-50.09%
Return on Assets-46.83%

Miscellaneous

Employees43
Outstanding Shares24,620,000

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics (NASDAQ:OVID) announced its earnings results on Tuesday, May, 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.06. View Ovid Therapeutics' Earnings History.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Ovid Therapeutics.

What price target have analysts set for OVID?

6 brokerages have issued 12-month price objectives for Ovid Therapeutics' stock. Their predictions range from $20.00 to $27.00. On average, they anticipate Ovid Therapeutics' share price to reach $23.50 in the next year. View Analyst Ratings for Ovid Therapeutics.

Who are some of Ovid Therapeutics' key competitors?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the folowing people:
  • Dr. Jeremy Max Levin, Chairman and Chief Exec. Officer (Age 65)
  • Dr. Amit Rakhit M.D., M.B.A., Chief Medical & Portfolio Management Officer (Age 48)
  • Dr. Dirk Haasner Ph.D., MPM, Sr. VP of Global Regulatory Affairs & Manufacturing (Age 53)
  • Dr. Matthew J. During M.D., DSc, FACP, FRACP, Founder, Pres, Chief Scientific Officer, Member of Scientific Advisory Board and Director (Age 61)
  • Dr. Yaron Werber M.D., Chief Financial Officer, Chief Bus. Officer, Treasurer and Sec. (Age 46)

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Has Ovid Therapeutics been receiving favorable news coverage?

News coverage about OVID stock has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ovid Therapeutics earned a news sentiment score of 0.17 on Accern's scale. They also assigned headlines about the company an impact score of 47.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include TAKEDA PHARMACEUTICAL COMPANY LTD (7.20%), BlackRock Inc. (5.52%), Redmile Group LLC (0.65%), Northern Trust Corp (0.48%), Millennium Management LLC (0.24%) and Schwab Charles Investment Management Inc. (0.14%). View Institutional Ownership Trends for Ovid Therapeutics.

Which institutional investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC. View Insider Buying and Selling for Ovid Therapeutics.

Which institutional investors are buying Ovid Therapeutics stock?

OVID stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Northern Trust Corp, JPMorgan Chase & Co., DRW Securities LLC, Schwab Charles Investment Management Inc., California State Teachers Retirement System and Spark Investment Management LLC. View Insider Buying and Selling for Ovid Therapeutics.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $8.28.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $214.96 million. The company earns $-64,800,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Ovid Therapeutics employs 43 workers across the globe.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]


MarketBeat Community Rating for Ovid Therapeutics (OVID)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ovid Therapeutics (NASDAQ:OVID) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Ovid Therapeutics in the last 12 months. Their average twelve-month price target is $23.50, suggesting that the stock has a possible upside of 183.82%. The high price target for OVID is $27.00 and the low price target for OVID is $20.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.50$23.50$23.50$23.50
Price Target Upside: 183.82% upside129.27% upside62.29% upside62.29% upside

Ovid Therapeutics (NASDAQ:OVID) Consensus Price Target History

Price Target History for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ:OVID) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2018Piper Jaffray CompaniesInitiated CoverageBuy$20.00HighView Rating Details
4/20/2018Ladenburg ThalmannInitiated CoverageBuy$27.00MediumView Rating Details
4/1/2018CowenReiterated RatingBuyHighView Rating Details
5/30/2017CitigroupInitiated CoverageBuy ➝ Buy$21.00HighView Rating Details
5/30/2017William BlairInitiated CoverageOutperform ➝ OutperformHighView Rating Details
5/30/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$26.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Ovid Therapeutics (NASDAQ:OVID) Earnings History and Estimates Chart

Earnings by Quarter for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ:OVID) Earnings Estimates

2018 EPS Consensus Estimate: ($2.13)
2019 EPS Consensus Estimate: ($2.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.48)($0.41)($0.45)
Q2 20182($0.61)($0.44)($0.53)
Q3 20182($0.67)($0.45)($0.56)
Q4 20182($0.69)($0.50)($0.60)
Q1 20192($0.71)($0.64)($0.68)
Q2 20192($0.73)($0.72)($0.73)
Q3 20192($0.74)($0.69)($0.72)
Q4 20192($0.76)($0.70)($0.73)

Ovid Therapeutics (NASDAQ OVID) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2018        
5/8/2018Q1 2018($0.48)($0.54)ViewN/AView Earnings Details
3/29/2018Q4 2017($0.39)($0.45)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.5370)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.4830)($0.57)ViewN/AView Earnings Details
6/13/2017Q1 2017($0.87)($3.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ovid Therapeutics (NASDAQ:OVID) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ovid Therapeutics (NASDAQ OVID) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 43.90%
Institutional Ownership Percentage: 29.26%
Insider Trading History for Ovid Therapeutics (NASDAQ:OVID)
Institutional Ownership by Quarter for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ OVID) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2017Jeremy M LevinCEOBuy15,334$7.15$109,638.104,601,529View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ovid Therapeutics (NASDAQ OVID) News Headlines

Source:
DateHeadline
Ovid Therapeutics (OVID) Coverage Initiated at Piper Jaffray CompaniesOvid Therapeutics (OVID) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - May 21 at 11:03 AM
-$0.61 Earnings Per Share Expected for Ovid Therapeutics (OVID) This Quarter-$0.61 Earnings Per Share Expected for Ovid Therapeutics (OVID) This Quarter
www.americanbankingnews.com - May 19 at 9:16 PM
Q2 2018 EPS Estimates for Ovid Therapeutics Cut by Analyst (OVID)Q2 2018 EPS Estimates for Ovid Therapeutics Cut by Analyst (OVID)
www.americanbankingnews.com - May 11 at 8:35 AM
Ovid Therapeutics (OVID) Downgraded by Zacks Investment ResearchOvid Therapeutics (OVID) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 10 at 2:13 PM
BRIEF-Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54BRIEF-Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54
www.reuters.com - May 9 at 9:43 AM
Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)
finance.yahoo.com - May 9 at 9:43 AM
Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate ProgressOvid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress
finance.yahoo.com - May 8 at 4:17 PM
Ovid Therapeutics (OVID) Cut to "Hold" at ValuEngineOvid Therapeutics (OVID) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM
Ovid Therapeutics (OVID) Receives Average Recommendation of "Buy" from BrokeragesOvid Therapeutics (OVID) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 5 at 1:33 AM
Ovid Therapeutics (OVID) Raised to "Buy" at ValuEngineOvid Therapeutics (OVID) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - May 2 at 10:58 PM
Ovid Therapeutics (OVID) Expected to Announce Earnings of -$0.48 Per ShareOvid Therapeutics (OVID) Expected to Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - May 2 at 11:25 AM
Ovid Therapeutics (OVID) Downgraded by Zacks Investment Research to SellOvid Therapeutics (OVID) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 25 at 11:30 AM
Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking CessationWired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation
finance.yahoo.com - April 25 at 9:49 AM
Ovid Therapeutics (OVID) Now Covered by Analysts at Ladenburg ThalmannOvid Therapeutics (OVID) Now Covered by Analysts at Ladenburg Thalmann
www.americanbankingnews.com - April 20 at 11:17 AM
 Analysts Anticipate Ovid Therapeutics (OVID) Will Post Earnings of -$0.48 Per Share Analysts Anticipate Ovid Therapeutics (OVID) Will Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - April 15 at 11:15 AM
Ovid Therapeutics (OVID) Stock Rating Upgraded by Zacks Investment ResearchOvid Therapeutics (OVID) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:47 AM
Ovid Therapeutics (OVID) Given Average Rating of "Buy" by AnalystsOvid Therapeutics (OVID) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 10 at 1:43 AM
Ovid Therapeutics (OVID) Upgraded to "Hold" by Zacks Investment ResearchOvid Therapeutics (OVID) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:03 AM
Zacks Investment Research Lowers Ovid Therapeutics (OVID) to SellZacks Investment Research Lowers Ovid Therapeutics (OVID) to Sell
www.americanbankingnews.com - April 5 at 10:57 AM
Q1 2018 Earnings Estimate for Ovid Therapeutics Issued By Piper Jaffray (OVID)Q1 2018 Earnings Estimate for Ovid Therapeutics Issued By Piper Jaffray (OVID)
www.americanbankingnews.com - April 5 at 8:36 AM
Ovid Therapeutics (OVID) Upgraded by ValuEngine to HoldOvid Therapeutics (OVID) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 3 at 10:55 AM
Ovid Therapeutics (OVID) "Buy" Rating Reiterated at CowenOvid Therapeutics' (OVID) "Buy" Rating Reiterated at Cowen
www.americanbankingnews.com - April 1 at 9:14 PM
Ovid Therapeutics (OVID) Posts  Earnings Results, Misses Expectations By $0.07 EPSOvid Therapeutics (OVID) Posts Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - March 29 at 5:30 PM
Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate ProgressOvid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress
finance.yahoo.com - March 29 at 4:17 PM
Ovid Therapeutics (OVID) Cut to "Hold" at Zacks Investment ResearchOvid Therapeutics (OVID) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:00 AM
Ovid Therapeutics (OVID) Presents At BioCenturys 25th Annual Future Leaders In The Biotech Industry Conference - SlideshowOvid Therapeutics (OVID) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow
seekingalpha.com - March 27 at 4:14 PM
Ovid Therapeutics (OVID) Scheduled to Post Earnings on ThursdayOvid Therapeutics (OVID) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 22 at 1:34 AM
Ovid Therapeutics (OVID) Rating Lowered to Sell at ValuEngineOvid Therapeutics (OVID) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - March 17 at 11:58 AM
Ovid Therapeutics (OVID) Says OV101 Granted Fast Track Designation by FDA for Treatment of Fragile X SyndromeOvid Therapeutics (OVID) Says OV101 Granted Fast Track Designation by FDA for Treatment of Fragile X Syndrome
www.streetinsider.com - March 16 at 5:11 PM
Ovid Therapeutics Inc (OVID) Given Consensus Rating of "Buy" by BrokeragesOvid Therapeutics Inc (OVID) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 16 at 1:36 AM
Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018
finance.yahoo.com - March 15 at 4:44 PM
BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome TreatmentBRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment
www.reuters.com - March 15 at 9:37 AM
Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X SyndromeOvid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome
finance.yahoo.com - March 15 at 9:37 AM
Lipocine (LPCN) versus Ovid Therapeutics (OVID) Critical ReviewLipocine (LPCN) versus Ovid Therapeutics (OVID) Critical Review
www.americanbankingnews.com - March 13 at 1:18 AM
Zacks: Analysts Anticipate Ovid Therapeutics Inc (OVID) Will Announce Earnings of -$0.42 Per ShareZacks: Analysts Anticipate Ovid Therapeutics Inc (OVID) Will Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - March 12 at 11:22 AM
ValuEngine Lowers Ovid Therapeutics (OVID) to SellValuEngine Lowers Ovid Therapeutics (OVID) to Sell
www.americanbankingnews.com - March 11 at 11:49 PM
Ovid Therapeutics (OVID) Research Coverage Started at Piper Jaffray CompaniesOvid Therapeutics (OVID) Research Coverage Started at Piper Jaffray Companies
www.americanbankingnews.com - March 10 at 12:00 AM
Ovid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual MeetingOvid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting
finance.yahoo.com - March 1 at 4:38 PM
Ovid Therapeutics (OVID) Presents At RBC Capital Markets Global Healthcare Conference - SlideshowOvid Therapeutics (OVID) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
seekingalpha.com - February 24 at 9:26 AM
Zacks: Analysts Expect Ovid Therapeutics Inc (OVID) to Announce -$0.42 Earnings Per ShareZacks: Analysts Expect Ovid Therapeutics Inc (OVID) to Announce -$0.42 Earnings Per Share
www.americanbankingnews.com - February 23 at 11:14 AM
Ovid Therapeutics Inc (OVID) Given Average Rating of "Buy" by AnalystsOvid Therapeutics Inc (OVID) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 19 at 1:30 AM
Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceOvid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 4:25 PM
Ovid Therapeutics (OVID) Upgraded to "Hold" at ValuEngineOvid Therapeutics (OVID) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 6:06 PM
Ovid Therapeutics Inc (OVID) Receives Consensus Recommendation of "Buy" from AnalystsOvid Therapeutics Inc (OVID) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 25 at 1:30 AM
Ovid Therapeutics (OVID) and Its Rivals Head to Head ContrastOvid Therapeutics (OVID) and Its Rivals Head to Head Contrast
www.americanbankingnews.com - January 24 at 5:14 AM
Ovid Therapeutics Inc (OVID) Expected to Announce Earnings of -$0.42 Per ShareOvid Therapeutics Inc (OVID) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - January 20 at 3:28 PM
Ovid Therapeutics (OVID) Lifted to "Buy" at Zacks Investment ResearchOvid Therapeutics (OVID) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 12:40 PM
Critical Contrast: Ovid Therapeutics (OVID) versus Its RivalsCritical Contrast: Ovid Therapeutics (OVID) versus Its Rivals
www.americanbankingnews.com - January 11 at 9:48 PM
Ovid Therapeutics (OVID) versus The Competition Financial ContrastOvid Therapeutics (OVID) versus The Competition Financial Contrast
www.americanbankingnews.com - January 10 at 11:14 PM
Critical Survey: Ovid Therapeutics (OVID) and The CompetitionCritical Survey: Ovid Therapeutics (OVID) and The Competition
www.americanbankingnews.com - January 9 at 7:08 PM

SEC Filings

Ovid Therapeutics (NASDAQ:OVID) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ovid Therapeutics (NASDAQ:OVID) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ovid Therapeutics (NASDAQ OVID) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.